Cochrane · systematic review · CD008123
Medical treatment for botulism
Chalk, CH, Benstead, TJ, Pound, JD, et al. · Cochrane Database of Systematic Reviews · 2019 · Cochrane Library
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
5
current version
GRADE rated
5
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 0 · 0%Low 1 · 20%Moderate 4 · 80%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Show all 2 versionsHuman‐derived botulinum immune globulin intravenous for infant botulism
Population: individuals with infant botulism
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
In‐hospital death from any cause occurring within 4 weeks of randomization or the beginning of treatment | no estimate extracted | 1 study · 122 participants | Moderate Downgraded: risk of bias |
Duration of hospitalization (in weeks) | no estimate extracted | 1 study · 122 participants | Moderate Downgraded: risk of bias |
Duration of mechanical ventilation (in weeks) | no estimate extracted | 1 study · 59 participants | Low Downgraded: risk of bias |
Duration of tube or parenteral feeding (in weeks) | no estimate extracted | 1 study · 122 participants | Moderate Downgraded: risk of bias |
Risk of adverse events (until time of hospital discharge) | RR 0.92 [0.72, 1.18] | 1 study · 129 participants | Moderate Downgraded: risk of bias |